Trials / Not Yet Recruiting
Not Yet RecruitingNCT06985576
Long-term Study to Evaluate Safety and Persistence of GF-CART01
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 18 (estimated)
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Detailed description
This comprehensive long-term follow-up study is meticulously designed to assess the safety and persistence of GF-CART01. Subjects who participated in the initial study of GF-01-01 and received treatment with GF-CART01, irrespective of their completion status, are eligible to participate in this follow-up study. The study may allow for a maximum enrollment of 18 subjects.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma (FL)
- Primary Mediastinal Large B-Cell Lymphoma
- High Grade B Cell Lymphoma
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2041-05-01
- Completion
- 2041-05-01
- First posted
- 2025-05-22
- Last updated
- 2025-12-18
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06985576. Inclusion in this directory is not an endorsement.